MétaCan
Menu
Back to cohort

Duration of Methadone and Buprenorphine-Naloxone Treatment

2025· article· en· W4411874434 on OpenAlexafffundabout
Robert A. Kleinman, Paul Kurdyak

Bibliographic record

VenueJAMA Network Open · 2025
Typearticle
Languageen
FieldMedicine
TopicOpioid Use Disorder Treatment
Canadian institutionsUniversity of TorontoCentre for Addiction and Mental Health
FundersUniversity of TorontoOntario Ministry of Health and Long-Term CareCentre for Addiction and Mental Health Foundation
KeywordsMedicineMethadoneBuprenorphine(+)-NaloxoneFentanylDiscontinuationOpioid use disorderOpioidAnesthesiaPopulationRetrospective cohort studyInternal medicine

Abstract

fetched live from OpenAlex

Importance: Fentanyl has spread through the illicit opioid supply in Canada, driving increasing overdose deaths. However, the effectiveness of methadone and buprenorphine-naloxone in treating opioid use disorder during the fentanyl era is unknown. Objective: To evaluate methadone and buprenorphine-naloxone treatment duration, a core effectiveness outcome in the treatment of opioid use disorder, in Ontario, Canada, between 2014 and 2022. Design, Setting, and Participants: This population-based, retrospective cohort study included individuals who initiated methadone or buprenorphine-naloxone between January 2014 and December 2022 in Ontario, Canada. Data were analyzed from July 18, 2023, to June 11, 2025. Exposure: Period of medication initiation (2014-2016, 2017-2019, or 2020-2022). Main Outcomes and Measures: The main outcome was treatment duration, measured as time to medication discontinuation (5 consecutive days without dispensation of the initial opioid agonist treatment or availability of take-home doses). Results: The cohort included 72 717 new recipients of opioid agonist treatments (45 256 [62.2%] male; median [IQR] age, 35 [28-46] years), with 34 538 individuals (47.5%) receiving methadone and 38 179 individuals (52.5%) receiving buprenorphine-naloxone. Among individuals starting methadone, median treatment duration decreased from 193 (95% CI, 185-202) days in 2014 to 2016 to 139 (95% CI, 130-149) days in 2017 to 2019 and 86 (95% CI, 78-95) days in 2020 to 2022. Among individuals starting buprenorphine-naloxone, median treatment duration decreased from 51 (95% CI, 49-54) days in 2014 to 2016 and 50 (95% CI, 48-53) days in 2017 to 2019 to 38 (95% CI, 36-40) days in 2020 to 2022. In adjusted Cox regression models including time-varying effects and using 2014 to 2016 as the reference period, hazards of discontinuation measured at treatment initiation were higher during later periods of methadone initiation (2017-2019: adjusted hazard ratio [aHR], 1.18 [95% CI, 1.15-1.22]; P < .001; 2020-2022: aHR, 1.45 [95% CI, 1.39-1.51]; P < .001) and for buprenorphine-naloxone initiation in 2020 to 2022 (aHR, 1.11 [95% CI, 1.08-1.15]; P < .001). Age categories, neighborhood income quintile, rurality, sex, and number of comorbidities were also associated with time to discontinuation in adjusted models. Conclusions and Relevance: This cohort study found that treatment duration among individuals starting methadone and buprenorphine-naloxone during 2020 to 2022 was lower than during 2014 to 2016. This study highlights the importance of ongoing evaluation of treatment effectiveness, given the dynamic nature of the opioid crisis. Further research is needed to improve treatment retention and improve the effectiveness of opioid use disorder treatment.

Fetched live from OpenAlex and de-inverted. Abstracts are not stored in this database: the inverted indexes are 8.6 GB of the frame’s 9.3 GB of text, and the host has 13 GB free.

How this classification was reachedexpand

Full frame distilled prediction

Teacher imitation

Not calibrated prevalence, not ground truth. Human validation pending. Learned from the 10,348 direct Codex labels and 10,348 direct Gemma labels. Candidate is the union of thresholded teacher heads; consensus is their intersection. These outputs are machine_predicted_unvalidated and are not human labels or direct frontier model labels.

metaresearch head score (Codex)0.000
metaresearch head score (Gemma)0.000
Version: codex-gemma-dda1882f352aValidation status: machine_predicted_unvalidated
Candidate categoriesnone
Consensus categoriesnone
DomainCandidate signal: none · Consensus signal: none
Study designCandidate signal: Observational · Consensus signal: Observational
GenreCandidate signal: Empirical · Consensus signal: Empirical
Teacher disagreement score0.240
Threshold uncertainty score0.437

Codex and Gemma teacher scores by category

CategoryCodexGemma
Metaresearch0.0000.000
Meta-epidemiology (narrow)0.0000.000
Meta-epidemiology (broad)0.0000.000
Bibliometrics0.0000.000
Science and technology studies0.0000.000
Scholarly communication0.0000.000
Open science0.0000.000
Research integrity0.0000.000
Insufficient payload (model declined to judge)0.0000.000

Machine scores (provisional)

The two teacher heads of the student model, read on this work. A score orders the frame for review; it never asserts a category, and the validation status ships verbatim with every row.

Baseline scores from an immature model (maturity gate not passed, 7 training rounds). Scores rank; they never assert a category.

Opus teacher head0.019
GPT teacher head0.311
Teacher spread0.292 · how far apart the two teachers sit on this one work
Validation statusscore_only:v0-immature-baseline · verbatim from the scoring run: score_only means the number may rank works, and no category label ships from it

Classification

machine, unvalidated

Machine predicted; a candidate call from one teacher head, not a consensus.

The models applied no category: nothing in the taxonomy fit this work.
Study designObservational
Domainnot available
GenreEmpirical

How this classification was reached, model by model and score by score, is at the end of the page under "How this classification was reached".

Quick stats

Citations6
Published2025
Admission routes3
Has abstractyes

Explore more

Same venueJAMA Network OpenSame topicOpioid Use Disorder TreatmentFrench-language works237,207